Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Introducing the Finviz Matrix

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Assembly Biosciences, Inc.

Contributing Author

Recent Articles by Assembly Biosciences, Inc.

6 hours
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program ASMB GlobeNewswire
Aug-13
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates ASMB +10.68% ASMB +10.02% GlobeNewswire
May-28
Assembly Biosciences Announces Upcoming Investor Conference Presentations ASMB GlobeNewswire
May-26
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares ASMB GlobeNewswire
May-22
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants ASMB +6.94% GlobeNewswire
May-22
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases ASMB +6.94% GlobeNewswire
May-13
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 ASMB GlobeNewswire
May-11
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference ASMB GlobeNewswire
May-07
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights ASMB GlobeNewswire
Apr-09
Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026 ASMB GlobeNewswire
Mar-19
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights ASMB GlobeNewswire
Dec-08
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes ASMB GlobeNewswire
Nov-10
Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates ASMB GlobeNewswire
Nov-07
Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting ASMB GlobeNewswire
Oct-14
Assembly Biosciences Announces Upcoming Investor Conference Participation ASMB GlobeNewswire
Oct-10
Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe ASMB GlobeNewswire
Aug-08
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings ASMB +12.96% GlobeNewswire
Aug-08
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes ASMB +12.96% GlobeNewswire
Aug-06
Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus ASMB ASMB +9.21% GlobeNewswire
Aug-06
Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates ASMB ASMB +9.21% GlobeNewswire
Jul-26
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop ASMB GlobeNewswire
Jun-30
Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179 ASMB GlobeNewswire
Jun-25
Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B ASMB GlobeNewswire
May-27
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference ASMB GlobeNewswire
May-08
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates ASMB -6.04% GlobeNewswire
May-07
New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025 ASMB GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)